BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 384248)

  • 1. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis.
    Hull R; Delmore T; Genton E; Hirsh J; Gent M; Sackett D; McLoughlin D; Armstrong P
    N Engl J Med; 1979 Oct; 301(16):855-8. PubMed ID: 384248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
    Hull R; Delmore T; Carter C; Hirsh J; Genton E; Gent M; Turpie G; McLaughlin D
    N Engl J Med; 1982 Jan; 306(4):189-94. PubMed ID: 7033782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
    Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
    N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.
    Hull RD; Raskob GE; Rosenbloom D; Panju AA; Brill-Edwards P; Ginsberg JS; Hirsh J; Martin GJ; Green D
    N Engl J Med; 1990 May; 322(18):1260-4. PubMed ID: 2183055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.
    Hull R; Hirsh J; Jay R; Carter C; England C; Gent M; Turpie AG; McLoughlin D; Dodd P; Thomas M; Raskob G; Ockelford P
    N Engl J Med; 1982 Dec; 307(27):1676-81. PubMed ID: 6755255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
    Hull RD; Raskob GE; Pineo GF; Green D; Trowbridge AA; Elliott CG; Lerner RG; Hall J; Sparling T; Brettell HR
    N Engl J Med; 1992 Apr; 326(15):975-82. PubMed ID: 1545850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
    Levine MN; Hirsh J; Gent M; Turpie AG; Weitz J; Ginsberg J; Geerts W; LeClerc J; Neemeh J; Powers P
    Thromb Haemost; 1995 Aug; 74(2):606-11. PubMed ID: 8584992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
    Arch Intern Med; 1997 Nov; 157(20):2317-21. PubMed ID: 9361572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis--a randomized clinical trial.
    Pini M; Pattachini C; Quintavalla R; Poli T; Megha A; Tagliaferri A; Manotti C; Dettori AG
    Thromb Haemost; 1990 Oct; 64(2):222-6. PubMed ID: 2270531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology and treatment of deep-vein thrombosis and pulmonary embolism.
    Carter BL; Jones ME; Waickman LA
    Clin Pharm; 1985; 4(3):279-96. PubMed ID: 3891200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.
    Hull RD; Raskob GE; Hirsh J; Jay RM; Leclerc JR; Geerts WH; Rosenbloom D; Sackett DL; Anderson C; Harrison L
    N Engl J Med; 1986 Oct; 315(18):1109-14. PubMed ID: 3531862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal therapeutic level of heparin therapy in patients with venous thrombosis.
    Hull RD; Raskob GE; Rosenbloom D; Lemaire J; Pineo GF; Baylis B; Ginsberg JS; Panju AA; Brill-Edwards P; Brant R
    Arch Intern Med; 1992 Aug; 152(8):1589-95. PubMed ID: 1497392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin and warfarin: use of anticoagulants in the prevention and treatment of venous thrombosis and pulmonary embolism.
    Rosen RL
    J Fam Pract; 1979 May; 8(5):923-7. PubMed ID: 438753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
    N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    Levine M; Gent M; Hirsh J; Leclerc J; Anderson D; Weitz J; Ginsberg J; Turpie AG; Demers C; Kovacs M
    N Engl J Med; 1996 Mar; 334(11):677-81. PubMed ID: 8594425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium.
    Berkowitz SD
    Orthopedics; 1995 Jul; 18 Suppl():18-20. PubMed ID: 7479421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.